Clinical Efficacy and Safety of Biodegradable Polymer‐based Sirolimus‐eluting Stents in Patients with Diabetes Mellitus Insight from the 4‐year Results of the Create Study
Yi Li,Yaling Han,Lei Zhang,Quanmin Jing,Xiaozeng Wang,Gaoliang Yan,Yingyan Ma,Geng Wang,Shouli Wang,Xuezhi Chen,Lixia Yang,Guoying Zhu,Huiliang Liu,Tieming Jiang
DOI: https://doi.org/10.1002/ccd.24649
IF: 2.3
2012-01-01
Catheterization and Cardiovascular Interventions
Abstract:BackgroundDiabetes mellitus is an independent predictor of adverse clinical events after drug‐eluting stent implantation.ObjectivesThe objective of this study is to evaluate the long‐term clinical efficacy and safety of biodegradable polymer‐based sirolimus‐eluting stents in diabetic versus non‐diabetic patients.MethodsA total of 2077 “all comers,” including 440 (21.2%) diabetic patients and 1637 (78.8%) non‐diabetic patients, were prospectively enrolled in the CREATE study at 59 centers in four countries. The recommended antiplatelet regimen was clopidogrel and aspirin for 6 months followed by chronic aspirin therapy. The primary outcome was the rate of major adverse cardiac events (MACE), defined as a composite of cardiac death, non‐fatal myocardial infarction (MI), and target lesion revascularization (TLR).ResultsDiabetic patients had higher risks of all‐cause death (8.2% vs. 3.4%, P < 0.001) and cardiac death (4.1% vs. 1.4%, P < 0.001) compared with non‐diabetic patients at 4 years. The rates of non‐fatal MI (0.2% vs. 0.9%, P = 0.218), TLR (2.0% vs. 2.8%, P = 0.357), MACE (5.9% vs. 4.4%, P = 0.227), and overall stent thrombosis (1.6% vs. 1.6%, P = 0.932) were not significantly different between diabetic and non‐diabetic patients. A landmark analysis showed that prolonged clopidogrel therapy (>6 months) was not beneficial in reducing the cumulative hazards of MACE either in diabetic or non‐diabetic patients (log rank P = 0.810).ConclusionsBiodegradable polymer‐based sirolimus‐eluting stents for the treatment of diabetic patients had a similar clinical event rate at 4 years compared with non‐diabetic patients, except for a higher mortality rate. © 2012 Wiley Periodicals, Inc.